Free Trial

Aspira Women's Health (AWH) Stock Price, News & Analysis

-0.16 (-6.99%)
(As of 02:38 PM ET)
Today's Range
50-Day Range
52-Week Range
46,804 shs
Average Volume
31,189 shs
Market Capitalization
$26.52 million
P/E Ratio
Dividend Yield
Price Target

Aspira Women's Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
108.9% Upside
$4.45 Price Target
Short Interest
2.18% of Float Sold Short
Dividend Strength
News Sentiment
-0.31mentions of Aspira Women
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.30) to ($0.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

791st out of 931 stocks

Diagnostic Substances Industry

11th out of 12 stocks

AWH stock logo

About Aspira Women's Health Stock (NASDAQ:AWH)

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

AWH Stock Price History

AWH Stock News Headlines

See More Headlines
Receive AWH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aspira Women's Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$9.15 million
Book Value
($0.23) per share


Free Float
Market Cap
$26.52 million
No Data
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

AWH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aspira Women's Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aspira Women's Health in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AWH shares.
View AWH analyst ratings
or view top-rated stocks.

What is Aspira Women's Health's stock price target for 2024?

2 Wall Street analysts have issued 12-month target prices for Aspira Women's Health's stock. Their AWH share price targets range from $3.30 to $5.60. On average, they predict the company's share price to reach $4.45 in the next year. This suggests a possible upside of 108.9% from the stock's current price.
View analysts price targets for AWH
or view top-rated stocks among Wall Street analysts.

How have AWH shares performed in 2024?

Aspira Women's Health's stock was trading at $4.08 at the beginning of 2024. Since then, AWH stock has decreased by 47.8% and is now trading at $2.13.
View the best growth stocks for 2024 here

When is Aspira Women's Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our AWH earnings forecast

How were Aspira Women's Health's earnings last quarter?

Aspira Women's Health Inc. (NASDAQ:AWH) issued its quarterly earnings data on Tuesday, May, 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.03. The business had revenue of $2.15 million for the quarter, compared to analyst estimates of $2.10 million. Aspira Women's Health had a negative trailing twelve-month return on equity of 1,099.32% and a negative net margin of 163.95%. During the same period last year, the business earned ($10.94) earnings per share.

When did Aspira Women's Health's stock split?

Shares of Aspira Women's Health reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Scott A. Carmilani's approval rating as Aspira Women's Health's CEO?

33 employees have rated Aspira Women's Health Chief Executive Officer Scott A. Carmilani on Scott A. Carmilani has an approval rating of 92% among the company's employees. This puts Scott A. Carmilani in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 97.0% of employees surveyed would recommend working at Aspira Women's Health to a friend.

What other stocks do shareholders of Aspira Women's Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aspira Women's Health investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and

Who are Aspira Women's Health's major shareholders?

Aspira Women's Health's stock is owned by a number of retail and institutional investors. Top institutional investors include B. Riley Wealth Advisors Inc. (1.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jack W Schuler, Minh Hoang Merchant, Nicole Sandford, Ryan Thinh Phan, Torsten Hombeck, Valerie Barber Palmieri and Veronica Gh Jordan.
View institutional ownership trends

How do I buy shares of Aspira Women's Health?

Shares of AWH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AWH) was last updated on 5/28/2024 by Staff

From Our Partners